Introduction {#sec1}
============

Lymphocyte B and T cells play central roles in adaptive immunity by mounting molecularly targeted responses against pathogens, providing both short-term and long-term immunological protection. Molecular recognition and specificity against foreign antigens is provided through adaptive immune receptors: B cell receptors (BCRs, referred to as antibodies in their secreted form) and T cell receptors (TCRs), which are both dimeric protein complexes consisting of heavy (HC) and light chains (LC) for BCR and alpha (α) and beta chains (β) (or γ and δ) for TCR. The diversity of both BCR and TCR needed for recognizing antigens is generated through combinatorial rearrangements of genomic germline variable, (diversity), joining segments (V(D)J recombination) during lymphocyte development ([@bib181]). Imprecise joining of these segments during V(D)J recombination leads to template-independent addition or deletion of nucleotides, which together with combinatorial pairing of receptor chains further increases diversity. Due to these diversification processes, each organism contains a highly unique B and T cell repertoire, in which their composition, dynamics, and evolution are constantly shaped by extrinsic (i.e., pathogens, vaccination) and intrinsic forces (i.e., tumors, autoimmunity, aging). This leaves each individual with a unique immunological fingerprint that provides information about the current and past states of adaptive immunity ([@bib69]).

Rapid progress in immune repertoire sequencing enables high-throughput interrogation of the genetic diversity of adaptive immune receptor repertoires at both the individual and population-wide level, thus providing unprecedented molecular insight on adaptive immunity in the context of infection, vaccination, aging, autoimmunity, and cancer ([@bib50]; [@bib61]; [@bib46]; [@bib9], [@bib10]). Immune receptor sequencing as well as recent progress in single-cell approaches excel at capturing the diversity of immune cell populations and their complex transcriptional profiles ([@bib127]). Increasing efforts are also being put into immunoinformatic tools to decode repertoire sequence information, with a primary goal of identifying specificity to antigens ([@bib95]; [@bib159]; [@bib23]). Furthermore, immunogenomic engineering platforms are being developed to interrogate immune receptors at high-throughput, which provides a means to unravel the functional properties of BCRs and TCRs and tune their specificity and selectivity ([@bib135]; [@bib51]). Recently, advances in genome editing technology are making it possible to reprogram the specificity and function of adaptive immune cells, which leads to the promise of generating "living drugs" that can sense and respond dynamically to disease targets ([@bib91]; [@bib98]). In this review, we will highlight methods from both systems and synthetic immunology, which are being utilized in a highly interdisciplinary manner to address fundamental questions in adaptive immunity and develop molecular and cellular immunotherapies ([Figure 1](#fig1){ref-type="fig"} ).Figure 1Reading, Writing, and Editing Adaptive Immunity with State-of-the-Art Methods Such as Immune Repertoire Sequencing, Immunoinformatics, and Immunogenomic EngineeringThe combination of these systems and synthetic immunology tools offers the possibility to answer long-standing immunological questions and to reprogram and engineer adaptive immunity.

Reading Adaptive Immunity by Immune Repertoire Sequencing {#sec1.1}
---------------------------------------------------------

Sequencing of adaptive immune receptor repertoires (BCRs and TCRs) has become an indispensable tool for the interrogation of the highly complex adaptive immune response. Being able to elucidate immune repertoire sequences and their quantitative composition on a nucleotide-level within and across individuals facilitates the identification of specific immune cells driving a response upon antigen recognition. When choosing from the variety of sequencing platforms, there are many aspects that need to be taken into consideration, such as sequencing depth, read length, and sequencing accuracy. Hereinafter, we provide a brief overview on the technological progress of sequencing platforms in the context of immune repertoires.

### Platforms for Immune Repertoire Sequencing {#sec1.1.1}

The emergence of deep sequencing platforms has enabled immune repertoire sequencing and analysis at a high-throughput level ([@bib196]; [@bib139], [@bib140]; [@bib53]; [@bib191]; [@bib192]; [@bib187]). Massively parallel sequencing was made possible due to the miniaturization and simultaneous operation of sequencing reactions on millions of DNA templates ([@bib109]). The most widely used technology from Illumina relies on DNA template amplification before sequencing in order to obtain sufficient signal for detection ([@bib116]). A variety of different instruments are provided by Illumina (e.g., MiSeq, HiSeq, NextSeq, and NovaSeq) with outputs ranging from 15 Gb and 25 million reads (MiSeq) to 6000 Gb and 20 billion reads (NovaSeq) with read lengths up to 300 bp (MiSeq). The overall error rate of all Illumina instruments is relatively low and lies around 0.1% with the most common error being single nucleotide substitutions ([@bib132]). Sequencing errors in immune repertoires lead to artificial increase of clonal diversity, as erroneous clones cannot be distinguished from naturally occurring clonal variants, leading to potentially flawed immunological interpretations. As Illumina platforms perform bridge amplification, it is possible to read both ends of the DNA fragments by paired-end sequencing and achieve longer read lengths (e.g., 2 x 300 bp). This is advantageous, as merging two overlapping reads can cover the entire variable regions of BCRs and TCRs and partially correct for errors in clonal identifier regions such as complementarity-determining region 3 (CDR3) ([@bib152]; [@bib54]). To date, well-established Illumina devices clearly dominate the field of immune repertoire sequencing, as they offer high-quality short-sequencing reads at unexcelled throughput. Deep resolution of the vast immune repertoire sequence space enables better insights into the diversity of unique BCR and TCR sequences (\>10^13^ in humans) and allows detection of shared clones across individuals, so called "public clones" ([@bib171]; [@bib21]; [@bib71]; [@bib43]).

Paired-end sequencing on Illumina allows coverage of one variable region of immune receptors; however, for approaches that rely on complete immune receptor sequence coverage and hence require longer read lengths, an alternative platform is offered by Pacific Biosciences (PacBio) ([@bib49]). PacBio\'s sequencing technology is based on single-molecule sequencing. Each DNA template molecule gets isolated in a microwell, together with a single polymerase and fluorescently labeled nucleotides. Importantly, the DNA templates are circularized before sequencing, allowing for repeated readout by the polymerase. This allows for consensus reading, achieving read accuracies of over 99% with high-fidelity read lengths up to 15 kb ([@bib198]). With the recent introduction of the PacBio Sequel II system, sequencing depths of 4 million reads per run can be achieved. Hence, PacBio can be utilized for sequencing immune receptor repertoires where variable regions (e.g., variable heavy (VH) and variable light (VL)) are physically linked in the context of single-cell sequencing ([@bib40]; [@bib114]). Moreover, long-read sequencing is in particular valuable for *in vitro* screening platforms (e.g., phage display), which for instance utilize recombinant antibody fragment libraries known as single-chain variable fragments (scFvs). Sequencing of full-length scFvs is important for covering both VH and VL diversity, which is critical in assessing quality of such libraries and their utility for drug discovery ([@bib77]; [@bib75]).

Finally, Oxford Nanopore offers another single-molecule sequencing platform with promising future implications for immune repertoire sequencing due to the capacity of producing ultra-long reads (up to 2 Mb) ([@bib32]; [@bib130]). This can be leveraged for the detection of additional diversification mechanisms in immune receptors, such as chromosomal integrations into variable regions ([@bib179]), as well as for studies combining transcriptome and V(D)J sequence analysis ([@bib33]; [@bib24]).

### Single-Cell Profiling of Immune Repertoires {#sec1.1.2}

Studies performing immune repertoire sequencing on bulk B or T cell populations mostly focus on one of the receptor transcripts, as for both BCR and TCR the corresponding VH/VL or Vα/Vβ chains are expressed as separate transcripts from different chromosomes, respectively. However, there is enormous value in obtaining single-cell resolution, as it provides essential information on natural pairing of variable chains, which enables deeper insights into the repertoire diversity and allows for validation of specificity with recombinant expression systems. In recent years, many innovative single-cell sequencing technologies based on droplet microfluidics, microwells, or combinatorial indexing have emerged with varying levels of throughput ([@bib41]; [@bib177]; [@bib86]; [@bib141]).

The commercial 10X Genomics Chromium technology uses automated droplet-based microfluidics for a variety of genomic approaches, most notably single-cell transcriptome sequencing ([@bib209]). Since the recent introduction of specific protocols and kits for targeted sequencing of BCR and TCR variable regions (V(D)J libraries), it has become the most widely used platform for single-cell immune repertoire sequencing. Its key features are gel beads in emulsion (GEMs) that incorporate a gel bead together with a single cell, enzymes, and poly(dT) primer. The GEM approach does not result in physical linkage of receptor chain transcripts, instead it relies on barcoding of cell-derived templates, thus providing a digital linkage of sequences. 5′ prime capture of full-length BCR/TCR transcripts ranging from 5′UTR to the constant regions are possible, thus allowing retrieval of variable region and isotype information of 100--10,000 cells per sample. Within one run, libraries of multiple samples can be prepared simultaneously with capture efficiencies of ∼50%−65%. Due to the fragmentation of amplicons, resulting V(D)J libraries can be short-read sequenced by Illumina platforms (e.g., 26 x 91 bp).

Using the 10X GEM system, Goldstein and colleagues performed single-cell sequencing from over 10^5^ B cells from different organisms ([@bib68]). They used antigen-baiting to label B cells from immunized animals, followed by flow cytometry enrichment and then 10X single-cell V(D)J sequencing. Based on the obtained information they recombinantly expressed a subset of the full-length VH-VL pairs and confirmed antigen-specific binding. This demonstrates the value of obtaining paired receptor data by high-throughput single-cell sequencing experiments in order to rapidly identify multiple antigen-binding antibodies. Along this line, Setliff et al. developed the method called "LIBRA-seq," which uses DNA-barcoded antigens to match BCR sequences with antigen specificity by a sequencing-based readout ([@bib158]). This approach led to the discovery of several HIV-1- and influenza-specific antibodies. In addition to rapid antibody discovery, LIBRA-seq holds promise for vaccine and immunotherapy development, as it allows screening of multiple antigens or epitopes at once. However, this strategy works only for B cells that have surface expression of BCRs. For cells that lack membrane-bound BCR (but secrete antibodies) such as plasma cells, a recent droplet-based microfluidic platform "CelliGO" was developed, which allows antigen-specific sorting and single-cell sequencing within one workflow ([@bib63]). Similar as for B cells, 10X Genomics can also be utilized for antigen-specific screening of T cells by the use of DNA-barcoded peptide-MHC multimers ([@bib126]).

In addition to profiling immune repertoires from single cells, there is substantial efforts to also integrate single-cell transcriptome data, as this provides deeper insight into the dependencies between immune cell clonal diversity and specificity with phenotype and function ([@bib151]; [@bib188]; [@bib178]; [@bib36]; [@bib3]). For example, Singh et al. combined targeted capture and long-read sequencing (Oxford Nanopore) of both BCR and TCR mRNA transcripts with short-read transcriptome sequencing (Illumina), all at a single-cell resolution ([@bib164]). This method was used on tumor-infiltrating lymphocytes from a human breast cancer patient, revealing the repertoire and gene expression profile of clonally expanded lymphocytes. Horns et al. combined 10X immune repertoire and transcriptome sequencing with bulk VH repertoire sequencing to profile human B cell responses to influenza vaccination ([@bib85]). The impact and benefit of performing both single-cell immune repertoire and transcriptome analysis becomes in particular evident during the outbreak of SARS-CoV2. Several studies performed single-cell sequencing on PBMCs from Covid-19 patients and were able to both phenotypically characterize immune cells as well as extract immune receptor sequences that correlated with infection ([@bib26]; [@bib99]; [@bib197]).

Immunoinformatics: Decoding of Immune Receptor Repertoires {#sec1.2}
----------------------------------------------------------

In the era of "big data," the use of specialized computational tools is crucial, in particular when interrogating the complexity of adaptive immunity. Immunoinformatics combines biological, computational, and statistical approaches. Its applications make use of genomic, proteomic as well as structural data and range from the study of immune-related genes and receptor epitope predictions to in-silico vaccination, among others ([@bib213]; [@bib23]). Although advances in antigen-specific single-cell sorting enable identification of receptor sequence and specificity, it is still restricted in throughput when compared to the depth of data generated by bulk immune repertoire sequencing. In this section, we will focus on immunoinformatic tools for decoding immune receptor repertoires obtained from sequencing studies ([Figure 2](#fig2){ref-type="fig"} ). In particular, we describe computational methods that are used in the discovery and characterization of (potential) antigen-specific immune receptors providing valuable information for the design of immune therapies.Figure 2Immunoinformatics Analysis and Visualization of Immune RepertoiresEach organism contains a highly unique B and T cell repertoire, generated by V(D)J recombination, whose composition, dynamics, and evolution gets shaped by extrinsic (i.e., pathogens, vaccination) and intrinsic forces (i.e., tumors, autoimmunity, aging). Diversity and clonal expansion within immune repertoires can be captured by, e.g., Hill-based diversity profiles, which include a continuum of diversity indices (clones get weighted by the parameter alpha---the higher alpha, the more weight is put on high-frequency clones). Clonal relationships and organization within immune repertoires can be inferred by network-based analysis with nodes representing unique clones, which are connected by edges depending on their sequence similarity. Connectivity degree distributions quantify the number of connections each node exhibits, thus providing insights into clonal expansion profiles. Clonal evolution analysis is in particular useful for B cells that undergo somatic hypermutation upon antigen recognition. Phylogenetic trees allow the reconstruction of both ancestral and intermediate relationships between B cell clonal sequences, thus facilitating the identification of affinity maturated clonal variants. Increasing efforts are put into detection of convergent immune responses upon antigenic challenge, e.g., via clonal overlap analysis for the discovery of shared clones across individuals or by the identification of shared sequence patterns. Machine- and deep learning models (e.g., support vector machines, random forests, or neural networks) can be used for the classification of immune receptor sequences into antigen-binder and nonbinder. For instance, these models can be trained on immune receptor sequences of known antigen specificity, which get encoded as numerical representations by methods such as k-mer decomposition or one-hot encoding.

### Data Pre-processing and V(D)J Assignment {#sec1.2.1}

Before performing in-depth immune repertoire sequencing analysis, the obtained raw data needs to be pre-processed in order to generate error-corrected sequences for proper analysis and interpretation. In short, pre-processing consists of removal of low-quality sequences and sequence length trimming (e.g., primer sequence removal). For paired-end sequencing, reads will be merged by consensus building. Advanced library preparation protocols that use unique molecular identifiers (UMIs) can be applied for error correction ([@bib160]; [@bib47]; [@bib183]; [@bib93]; [@bib55]; [@bib104]; [@bib4]), which is highly advantageous for obtaining accurate information on clonal diversity.

As each receptor sequence is a product of somatic recombination with possible N/P nucleotide editing and somatic hypermutation (for B cells), each sequence needs to be assigned to its corresponding unmutated V(D)J germline segments. However, the high variability present in repertoire sequences can make assignments to germline a complicated task. In addition, the number of allelic variants is large and still not fully known, hence, reference germline databases are only partially complete ([@bib35]; [@bib125]; [@bib149]; [@bib193]). Proper V(D)J assignments strongly depend on the completeness of those databases as well as on the choice of annotation software packages to infer utilized V(D)J segments ([@bib167]; [@bib102]). There is a variety of software tools that can be utilized for data pre-processing and/or V(D)J alignment, e.g., pRESTO and Change-O ([@bib185]; [@bib74]), MiXCR ([@bib216]), IMGT ([@bib64]; [@bib6]), and IgBlast ([@bib203]), and for new germline allele identification, e.g., TIgGER ([@bib59], [@bib58]) and IgDiscover ([@bib35])).

### Clonal Analysis {#sec1.2.2}

Clonal selection and expansion are foundational principles of adaptive immunity, where the biological definition of clones is a subset of cells that originated from a common ancestor (e.g., naive B cell or T cell). Therefore, the bioinformatic definition of clones in immune repertoire sequencing data is crucial for downstream analysis. The clonal grouping or clustering approach, also referred to as clonotyping, is usually based on the more diverse VH for BCR and Vβ chain for TCR. Special attention is given to the junction of V(D)J recombination: the CDR3, which is the most variable region and decisive for antigen recognition and binding, thus the VH/Vβ CDR3 are preferentially used to identify BCR and TCR clones. For T cells, all identical TCR sequences represent a unique clone, for B cells however, inferring clones and their clonal lineage is nontrivial, as clonal members often do not comprise identical V(D)J sequences due to somatic hypermutation ([@bib78]). The most common clonotyping strategy for the identification of clonally related B cells utilizes a distance-based approach via hierarchical clustering ([@bib202]; [@bib70]). Briefly, BCR sequences with the same annotated V- and J-gene germline segments and same junction length are grouped together, and those sequences that possess a junction similarity above a set threshold (e.g., 80%--90%) are defined as originating from the same clone (same can be done for the LC). However, setting a fixed distance cut-off for clonal definition is far from ideal, as it cannot account for different levels of clonal diversification within a repertoire. Therefore, much effort is put into more advanced and alternative strategies that make use of different grouping criteria or thresholds to infer clones, including ones based on probabilistic models or spectral clustering with adaptive thresholds ([@bib136]; [@bib123]; [@bib124]). Just recently, Lindenbaum and colleagues introduced an alignment-free method bypassing initial V- and J-gene assignments ([@bib100]).

### Diversity Profiles {#sec1.2.3}

Upon antigen recognition and activation, certain subsets of B and T cells undergo extensive proliferation (and affinity maturation in the case for B cells). This induces temporal changes in immune repertoire dynamics and composition, which can be captured by diversity profiles. Such quantitative analysis on a global repertoire level is of interest when investigating vaccination response or discriminating between health and disease. Diversity measurements for immune repertoires are adapted from mathematical ecology, which are used to assess the diversities of ecosystems. Commonly used diversity measures include species richness, Shannon\'s entropy, and Simpson\'s index, among others, which differ in their weighting of rare clones ([@bib28]). However, they are sensitive to sampling depth and results can vary depending on which diversity index is used. In order to visualize full clone size distribution, Hill-based diversity profiles that include a continuum of single diversity indices (including the above-mentioned ones) can be used ([@bib69]; [@bib143]).

### Clonal Evolution {#sec1.2.4}

Because B cells can undergo somatic hypermutation upon antigen recognition, a B cell lineage is generated, which consists of BCR sequence variants that share the same specificity but with different affinities. Phylogenetic trees are often used to reconstruct both ancestral and intermediate relationships between B cell clonal sequences, thereby enabling tracking of clonal evolution, which can be in particular indicative of antigen specificity ([@bib204]; [@bib80], [@bib81]) (note: lineage tree construction might be integrated into the clonotyping step). Commonly used phylogenetic methods range from maximum parsimony and maximum likelihood to Bayesian analysis. Using maximum parsimony, phylogenetic trees are reconstructed by assuming the least amount of mutations, whereas the other methodologies include substitution models or probabilistic priors that can incorporate certain features thought to impact sequence evolution such as mutation rates ([@bib205], [@bib204]; [@bib82]; [@bib214]; [@bib201]). Under the assumption that B cell affinity maturation drives improved affinity, study of the tree topology may reveal clonal selection and allow the identification of clonal sequences or features correlating with increased affinities toward the antigen of interest. Reconstruction of the evolutionary path of antigen-reactive B cells is of particular use in the field of rational vaccine design, e.g., for HIV research, in which increased somatic hypermutation levels are known to be important features of broadly neutralizing antibodies (bNAbs). Extensive studies led to the discovery of a panel of HIV Env-specific bNAbs; these B cells evolved in different patients after years of chronic infection but exhibited common sequence elements depending on the epitope being recognized ([@bib201]; [@bib212]). Thus, efforts are undertaken to rationally design immunogens that specifically target germline-precursor B cells to induce their maturation toward bNAb secreting cells---a promising approach referred to as "germline targeting" ([@bib170]; [@bib22]; [@bib89]; [@bib175]).

### Network Analysis {#sec1.2.5}

Network-based analysis offers another possibility to infer clonal relationships and their organization within immune repertoires based on sequence similarity. In an immune repertoire network, nodes represent unique clones (CDR3 or full V(D)J sequences) that are connected by edges depending on their sequence similarity. Sequence distance matrix calculations are usually based on Levenshtein or hamming distance (e.g., with a Levenshtein distance cut-off of 1, only those nodes are connected that differ at most by one nucleotide or amino acid). This approach allows visualization and detection of clonal clusters that build up a unique repertoire architecture. For quantitative analysis, metrics describing each repertoire architecture on a global as well as on a local level can be deployed. For instance, measuring the connectivity degree distribution, meaning quantifying the number of connections each node exhibits, provides insights into the clonal expansion profile of the repertoire in question. Dissecting clonal clusters that exhibit high connectivity (intraclonal diversity) as well as integrating clonal frequency information may thus offer hints on antigen-induced expansion of specific clones ([@bib11]; [@bib119]). Of note, network-based analysis allowed the characterization of public clones showing that they tend to be highly connected and associated with maintaining the repertoire architecture. Madi and others performed a network-based analysis of both murine and human immune repertoires and observed that public clones were found to be among the most connected nodes, possibly providing a common basis for functional immunity ([@bib105]; [@bib118]). Albeit the emergence and functionality of public clones are not yet fully understood, there is increasing evidence for their role in neutralization of common pathogenic antigens, autoimmune diseases, and cross-reactivity ([@bib106]; [@bib72]; [@bib208]; [@bib78]; [@bib94]). Recently, public T cell clones have been shown to recognize peptides on multiple HLAs, which makes them a promising target for immunotherapy ([@bib60]). Furthermore, the identification of public clones is of particular interest for population-wide targeting in the context of vaccine design ([@bib157]).

### Clonal Convergence and Identification of Antigen-Specific Patterns {#sec1.2.6}

The occurrence of identical or similar shared immune receptor sequences within or across different individuals in response to an antigenic challenge hints toward the concept of antigen-associated clonal convergence ([@bib128]; [@bib182]; [@bib50]; [@bib134]; [@bib48]; [@bib5]). One straightforward approach to identify clones that specifically arose upon an antigenic challenge is to perform overlap analysis, which can be visualized with Venn diagrams. Frequency information can also be included for pairwise quantitative comparisons by applying metrics such as the Morisita-Horn overlap index or the cosine-similarity metric ([@bib142]; [@bib115]). However, the enormous immune receptor diversity makes antigen-driven public clones based on exact immune receptor sequence a statistically unlikely event. Thus, increasing efforts are being undertaken to develop advanced clustering tools to detect sequence patterns that hint toward antigen-driven repertoire convergence ([@bib39]; [@bib133]; [@bib117]; [@bib207]).

Two seminal approaches performed by Dash et al. and Glanville et al. utilized immune repertoire sequencing of antigen-specific single T cells for the detection of sequence motif patterns that were associated with a specific peptide-MHC antigen ([@bib217]; [@bib67]). Dash and colleagues utilized a CDR-weighted distance metric to measure similarity between any TCR sequences (TCRdist) ([@bib217]). Glanville and colleagues developed an algorithm called GLIPH for identifying TCR specificity groups, where all TCRs in a group recognize identical or highly similar pMHC ligands. Also here, conserved motifs as well as global similarity between CDRs (in particular CDR3s) are used in the clustering approach. GLIPH can be used directly on TCR repertoires without prior knowledge of antigen specificities, to identify TCRs with shared specificity as well as their HLA restriction ([@bib67]; [@bib215]). Using the insights on antigen-specific TCR sequence motifs, both groups developed a classification system with which they could predict antigen specificity with high accuracy.

Along this line, increasing efforts were put into the development of novel bioinformatic, statistical, and machine learning models; these include hidden Markov models (HMMs) and support vector machines (SVMs), decision trees, or artificial neural networks (ANNs) ([@bib111]; [@bib72]; [@bib199]; [@bib97]; [@bib162]; [@bib52]). For example, immune receptor sequences identified through antigen-specific cell sorting can be grouped into antigen-specific binders and nonbinders. All sequences then get encoded as numerical representations by methods such as one-hot encoding, k-mer decomposition, or vector embedding. Utilizing classical machine learning or more advanced deep learning models, one can then train and fine-tune the models using the embedded sequences for which specificity is already known in such a way that the models are later able to classify unseen input sequences into binder and nonbinder. Of note, due to the increased usage of these novel machine- and deep learning strategies, models for in-silico simulation of immune repertoires are highly valuable for a better understanding, training, and evaluation of such complex computational tools ([@bib195]; [@bib205]; [@bib108]; [@bib156]; [@bib148]).

Just recently, Friedensohn and colleagues developed an unsupervised deep learning approach for the identification of convergent antibody sequence clusters from bulk BCR repertoires (not antigen-sorted) ([@bib56]). Briefly, they performed immune repertoire sequencing of antibody VH chains from four different cohorts of immunized mice. The resulting sequences were used for training of a variational autoencoder (VAE) combined with a Gaussian mixture model (GMM), which clustered the encoded sequences in a lower dimensional latent space. Cluster membership of novel, unseen sequences could then be used to predict their antigen specificity. Moreover, cluster-derived sequences as well as in-silico generated sequences were recombinantly expressed and shown to be specific for the corresponding antigen.

Progress in the field of deep learning approaches has promising implications for rational guided immune receptor design. As demonstrated in the studies of Glanville et al. and Friedensohn et al., the identification of antigen-specific motifs or clusters can be leveraged for in-silico generation of de novo antigen-specific variants ([@bib67]; [@bib56]; [@bib7]). Thus, different deep learning models can be trained (e.g., with sequences derived from large combinatorial mutagenesis libraries) and used to identify antigen-specific sequences with improved features such as optimized affinity or developability parameters out of both natural or in-silico-generated immune receptor sequences. This has promising implications for time and cost-effective immune receptor engineering and optimization approaches ([@bib111]; [@bib29]; [@bib101]).

Immune Receptor Engineering with Synthetic Display Platforms {#sec1.3}
------------------------------------------------------------

One of the most widely utilized synthetic platforms is phage display, which relies on genetic encoding and expression of the variable regions of an immune receptor (as a fusion to viral capsid protein), thus providing a phenotype-genotype linkage ([@bib168]). The displayed variable domains when derived from a BCR/antibody can either be in an scFv format in which the VL and VH domains are connected via a peptide linker or in a fragment antigen-binding (Fab) format, which consists of the variable and the first constant domain of each light and heavy chain. In the context of a TCR, direct display is challenging due to low stability and expression of a soluble TCR, thus the most common format uses disulfide-bond-linked TCRs (dsTCRs) in which additional disulfide bonds increase the stability ([@bib19]) or the scTCR format in which the alpha and beta chain are connected via a peptide linker. One of the main advantages of phage display over other synthetic platforms is the ability to create very large recombinant libraries of up to 10^11^ variants. These libraries are constructed either from natural immune repertoires (e.g., infected patients or immunized animals) or synthetic repertoires via different mutagenesis and DNA synthesis approaches. Phage libraries are screened via biopanning, which involves the addition of the library to immobilized antigen, washing out unbound phage variants, and finally eluting bound phages. The bound phages are then amplified and subjected to multiple rounds of panning to enrich for antigen-specific phage. The introduction of immune repertoire sequencing in the phage display screening process gives valuable insights, guides the selection process, and improves library design ([@bib8]; [@bib45]; [@bib66]; [@bib138]). Deep sequencing of panning rounds has uncovered that many high-affinity binding clones become depleted due to fitness costs and that enriched clones identified can exhibit higher antigen selectivity ([@bib138]; [@bib150]; [@bib191]). To recover specific clones, immune repertoire sequencing data can be used to design primers that bind to the CDRH3 region of a specific clone and amplify it via an inverse PCR approach ([@bib172]).

Another powerful platform is yeast display, where variable regions of immune receptors are fused to yeast surface protein ([@bib17]). Similar to phage display, an antibody or TCR can be displayed on yeast in scFv, Fab, or scTCR formats ([@bib165]; [@bib96]; [@bib83]; [@bib169]). Yeast display libraries can be screened with a significant advantage of utilizing fluorescence-associated cell sorting (FACS), which provides real-time assessment and quantitative characterization of the binding properties of receptor variants. Compared with phage the maximum library size of yeast is smaller with 10^9^ - 10^10^ variants ([@bib13]), but due to efficient homologous recombination in yeast there is no need for cloning *in vitro*, which simplifies the construction of libraries ([@bib103]). Another advantage of yeast is the presence of protein folding control, posttranslational modifications, and glycosylation, resulting in immune receptors with more stable properties, which is particularly important for antibody drug development ([@bib16]).

Immune Receptor Engineering with Synthetic Immune Cell Platforms {#sec1.4}
----------------------------------------------------------------

Although phage and yeast display are able to express immune receptor fragments, they both still lack important features present in the naive expression of immune receptors by B and T cells. For example, certain receptor frameworks are difficult to express in bacteria or yeast cells and are therefore lost. Furthermore, expression as in the truncated scFv or Fab format does not always successfully translate into the IgG format, thus slowing or preventing the development of therapeutic antibodies. Furthermore, scTCR binding does not necessarily point to eventual TCR signaling. Although it is fast and inexpensive to recombinantly express proteins in bacteria or yeast using standard DNA plasmid systems, mammalian cells do not replicate plasmids. In order to use repeated cycles of mutagenesis and selection rounds akin to yeast and phage, advanced genome editing tools are necessary. With the advent and rapid advancement of CRISPR-based methods, mammalian display has entered an exciting new stage with opportunities for engineering immune receptors. In the following sections, we will briefly explain CRISPR systems and elaborate how these can be applied to mammalian display platforms to engineer specificity, selectivity, and functionality of immune receptors.

### CRISPR-based Genome Editing {#sec1.4.1}

Since its adaptation to mammalian cells in 2013 ([@bib34]), the CRISPR/Cas9 system has dominated the field of genome editing, due to its versatility, simplicity, and efficiency. CRISPR/Cas9 was discovered in bacteria as a form of adaptive immunity against phage viruses. As a genome editing tool, the system consists of only two main parts: the Cas9 nuclease enzyme and the guide RNA (gRNA). Beyond Cas9, many related CRISPR systems have been discovered, repurposed, and utilized for various applications, including immune cell manipulations of both RNA and DNA. Although natural DNA repair mechanisms are leveraged by designer nucleases, novel approaches rely on targeting other effectors to specific regions of the genome, such as nucleotide-converting enzymes (Base editors) or reverse transcriptases (Prime editing), to directly synthesize a desired edit into a DNA nick. Despite their utility in other fields ([@bib194]), these are less suited to cause profound changes in immune cells, because they can only be used to modify a small region within the genome ([@bib110]).

CRISPR systems are still in their infancy in regard to medical translatability, not yet reaching the more extensively used classical genome modification tools (e.g., retroviruses, lentiviruses, adeno-associated viruses and zinc-finger nucleases). In a clinical context, only Cas9 has been tested so far and concluded to be safe for use in treating patients with CRISPR-modified T cells expressing cancer-specific chimeric antigen receptors (CARs), which showed promising results related to efficacy and safety ([@bib174]).

### Antibody Screening with Mammalian Display {#sec1.4.2}

One of the first mammalian display approaches was based on HEK-293T cells transiently transfected with plasmids encoding an scFv library. Because the scFv was fused to the transmembrane domain of human-platelet-derived growth factor receptor (PDGFR), it was displayed on the cell surface ([@bib79]). Similar to yeast display, the mammalian cell library was screened via flow cytometry. One drawback of this transient transfection approach is that the number of plasmids per cell is variable and therefore results in the expression of multiple scFv variants per single cell as well as expression level fluctuations due to different plasmid copy numbers. Furthermore, the expression is temporary, which prevents multiple rounds of enrichment or downstream assays. One approach to overcome transient expression consists of using the sindbis virus to stably integrate scFv in the genome of BAK cells, which enabled the long-term display of scFv on the surface of mammalian cells ([@bib12]). However, because the sindbis virus randomly integrates in the genome, the problem of multiple variants and copies per cell was not solved. To address this challenge, a genome integration system was developed based on the Flp recombinase (Flp-In cell line developed by Invitrogen), which enabled site-specific single copy integration and through fusion with the transmembrane domain of PDGFR resulted in the display of full IgG on the surface of CHO cells ([@bib210]). Because therapeutic antibodies are administered in the secreted format and many functional and developability assays require soluble antibodies, several approaches have been developed to enable display but also secretion of antibodies in the same platform. One approach used Cre recombination sites flanking the transmembrane domain, which facilitated Cre-mediated deletion of the transmembrane domain and therefore switching from antibody display to antibody secretion ([@bib180]). Another approach used the RIRR sequence that can be recognized and partially cleaved by the furin enzyme, leading to simultaneous secretion and display of antibodies ([@bib211]). Yet another approach is based on alternative splicing, thus allowing titration of the secretion to display ratio ([@bib2]; [@bib84]). More recently, several novel mammalian display platforms have been developed by taking advantage of CRISPR systems ([Figure 3](#fig3){ref-type="fig"} ). For example, Pogson and Parola et al. used Cas9 and homology-directed repair (HDR) to exchange antibody sequences at the endogenous immunoglobulin locus of a hybridoma cell line, thus enabling endogenous promoter driven expression, display as well as secretion of full-length IgG ([@bib135]; [@bib129]). Furthermore, Mason et al. established the constitutive expression of Cas9 in this cell line and demonstrated that Cas9 HDR with degenerate oligonucleotide templates could be used to generate mutagenesis libraries into antibody variable regions with high efficiency ([@bib112]).Figure 3Synthetic Mammalian Display Platforms for the Discovery and Engineering of Immune ReceptorsThe construction of large mammalian receptor libraries is becoming possible due to novel genome editing tools such as CRISPR/Cas9 that can be used to introduce diversity in the immune receptor locus of B or T cell lines. These cell libraries can be screened using high-throughput methods to assess affinity, specificity, and functional activity. For the selection of immune receptors with a desired affinity and specificity, fluorescence-activated cell sorting (FACS) and magnetic-activated cell sorting (MACS) can be utilized. Functional receptor activity on the other hand can be assessed via co-culture systems that include a target presenting cell line that activates the receptor signaling pathway of the library cell line followed by subsequent screening based on signaling activity via FACS.

### T Cell Platforms for Functional TCR Engineering {#sec1.4.3}

Functional screening platforms for interrogation of engineered TCRs outside of the primary cell context are useful tools to approach challenges related to safety, specificity, developability, and efficacy of T cell therapies. Despite a plethora of reports on the utilization of CRISPR in immortalized Jurkat T cell lines ([@bib31]; [@bib163]; [@bib20]; [@bib18]; [@bib27]), functional engineering of TCRs in this context has received little attention.

The first efforts in the field of testing TCRs in Jurkats was accomplished by equipping TCR-negative Jurkat T cells with a tumor-specific TCR through retroviral integration. Activation of the TCR was measured through an NFAT-Luciferase reporter ([@bib1]); however the TCRs either did not activate or activated only weakly. CD8 was identified as an important driver of T cell activation ([@bib42]), and the lack thereof may explain why Jurkats (which are CD4+) were inadequate to simulate T cell activation for cancer recognition. Aarnoudse and colleagues consequently generated CD8+ Jurkats through retroviral transduction. Nonendogenous behavior meant that modification of Jurkats was necessary to transform them into a viable platform for TCR engineering. Because of this, activation in a cellular context has been subpar in evaluating TCR functionality for TCR engineering. Fast and inexpensive functional screening of transiently expressed TCRs in CD8+ and CD4+ Jurkats has been established, but the transient nature prevented further engineering approaches and selections. Current research in the field has been overwhelmingly focused on affinity-based selections of TCRs ([@bib92]; [@bib30]; [@bib107]; [@bib154]; [@bib190]; [@bib173]). As highlighted in previous sections, affinity maturation of scTCR-pMHC pairs has been done by phage and yeast display screening. However, these display technologies exhibit rather poor scTCR expression and stability, and most importantly they are unable to interrogate the natural physiological context of TCR functional specificity---antigen-induced activation of TCR signaling pathways. Modifications to the TCR structure have been made recently, enabling improved expression and folding ([@bib73]; [@bib57]).

Current approaches for TCR engineering heavily rely on affinity maturation to improve engineered T cell proliferation, cytokine secretion, and cytotoxicity. This is based on the notion that the affinity and function of T-cell-mediated responses are correlated ([@bib206]; [@bib153]). However, despite this common assumption, several reports on modeling and screening TCR-pMHC interactions suggest that more research is necessary ([@bib62]; [@bib15]; [@bib161]). Affinity maturation, however, seems necessary to engineer soluble TCRs or cell therapies because naturally occurring TCRs are often too low affinity to be effective.

Unfortunately, TCRs engineered for higher affinity binding to peptide-MHC as well as TCRs derived from transgenic mice have been linked to patient deaths in cell therapy clinical trials. Currently on-going clinical trials have raised further safety concerns ([NCT04044768](ncbi-geo:NCT04044768){#intref0010}, [NCT02592577](ncbi-geo:NCT02592577){#intref0015}). These outcomes are related to the fact that TCRs can possess a broad, cross-reactive specificity profile, in some cases recognizing thousands of different peptide off-targets ([@bib14]). In one clinical trial, a TCR derived from an immunized transgenic mouse targeting the tumor-associated antigen MAGE-A3 peptide was discovered to be cross-reactive toward a similar peptide, (MAGE-A12), displayed in the brain, leading to severe neurotoxicity including patient death ([@bib121]). Another TCR targeting MAGE-A3, this time derived from an immunized patient and affinity matured through phage display, was used in a clinical trial, also leading to patient death. Retrospectively, it was discovered that this engineered TCR possessed cross-reactivity to titin-peptide expressed on cardiomyocytes and was the source of the observed severe cardiotoxicity. Engineering by phage display actually introduced mutations that led to cross-reactivity with titin ([@bib25]).

A number of reports demonstrate the use of mammalian cells for TCR screening and engineering, most of which involved viral transformations and affinity-based selections ([@bib92]; [@bib30]; [@bib107]; [@bib154]; [@bib190]; [@bib173]). In order to overcome the challenges related to TCR affinity and cross-reactivity, it is necessary to engineer TCR specificity not only on the basis of binding and function ([@bib144]), but also while detecting cross-reactivity. To that end, the recently established TCR-accepting T cell (TnT) platform was developed through several CRISPR-editing steps in the Jurkat T cell line ([@bib186]). Combining CRISPR-targeting, functional selections and immune repertoire sequencing, it was possible to profile mutational landscapes of tumor-specific TCRs, as well as accurately predicting off-targets that led to patient deaths in engineered TCR clinical trials. In addition, the authors showed that TnT cells could be used to engineer synthetic TCR variants with enhanced affinity to the MAGE-A3 cancer antigen with no detectable cross-reactivity, representing promising and safe clinical candidates for TCR cell therapy.

### Engineering Chimeric Antigen Receptors {#sec1.4.4}

Chimeric antigen receptors (CARs) and their antigen-binding domains are often discovered or engineered using phage and yeast display, resulting in high-affinity scFvs. Similar to high-affinity TCRs, these high-affinity CAR T cells may exhibit significant toxicities due to on-target off-tumor activity. Therefore, understanding the relationship between affinity, selectivity, and CAR activation is crucial to creating safer and more efficacious treatments. In a recent report, reducing the affinity and increasing the valency/avidity of an scFv enhanced the ability of CAR T cells to distinguish between normal and tumor cells ([@bib166]). It is also possible to quickly evaluate new CAR constructs in a mammalian reporter cell line by relying on an NFAT and NFkB dual-fluorescent reporter system upon stimulation ([@bib147]). This cell line was generated using viral transductions and transposon-mediated integration of an scFv library targeting the tumor-associated antigen ROR1, which was screened to identify scFv variants that showed improved signaling. However, due to difficulties with multiple, transposase-mediated genomic insertions, discerning the effect of single variants was challenging. Recently, a CRISPR-mediated CAR T cell reporter cell line was generated ([@bib44]). This platform was used to identify CAR variants that were highly active and selective for high antigen expression levels. Site-saturation mutagenesis libraries of the scFv were screened, followed by immune repertoire sequencing. Selection for both signaling and binding guided the isolation of specific variants with enhanced antigen level discrimination. Interestingly, the authors report a striking divergence between affinity and CAR T cell responsiveness profiles, indicating again the importance of functional screening.

Engineering Synthetic Immunity {#sec1.5}
------------------------------

Active and passive immunizations (e.g., antibody serum therapy) have been clinically used for over a century. These established therapeutics have eradicated a large number of pathogenic diseases and continue to be relevant for novel diseases (e.g., Covid-19). However, some pathogens and afflictions continue to elude natural immunity, such as HIV and cancer. In some cases, it may be necessary to move past active and passive immunization and combine both into a novel concept of synthetic immunity, in which adaptive immune responses are engineered on a cellular level. Recent success in treating hematological cancers due to the approval of CAR T cell therapies are testament to this. In the following sections, we will discuss the theoretical basis and progress to date in respect to engineering adaptive immune responses in T cells and B cells by genome editing ([Figure 4](#fig4){ref-type="fig"} ).Figure 4Workflow of Adoptive Cellular Therapy(A--E) (A) First, B or T cells are isolated from whole blood or PBMCs. Pure lymphocyte populations are (B) re-engineered using CRISPR systems. (C) After *ex vivo* expansion, (D) autologous cells are infused into the patient, (E) where they exert their effector functions either by attacking cancer cells (modified T cells) or by homing to lymphoid tissue to differentiate and secrete antibodies that confer a synthetic immunity toward pathogens.

### CRISPR-Mediated T Cell Engineering {#sec1.5.1}

Adoptive T cell transfers to cure cancer are not a recent idea. Tumor infiltrating lymphocytes (TILs) were extracted, expanded, and used in the 1980s, achieving durable remissions in some patients. A plethora of tumor evasion mechanisms such as downregulation of MHC or the secretion of immune modulators, as well as the complex manufacturing negatively impacted the success of adoptively transferred TILs. In the late 1980s, new tools were developed that facilitated the manipulation of T cells, driven by advances in DNA reading, writing, and editing, thus enabling the delivery of exogenous DNA and its detection in immune cells. Despite recent clinical successes in treating hematological tumors with engineered CAR T cells, considerable limitations and safety concerns persist. In the following sections, we will highlight the major developments in engineering T cells as potent immunotherapies.

As already highlighted, CRISPR is still at a very early stage regarding clinical translation, as there are currently no CRISPR-based cell therapies approved by the FDA or EMA but there are a number of ongoing clinical trials ([clinicaltrials.gov](http://clinicaltrials.gov){#intref0020}, [NCT03752541](ncbi-geo:NCT03752541){#intref0025}, [NCT04026100](ncbi-geo:NCT04026100){#intref0030}, [NCT03166878](ncbi-geo:NCT03166878){#intref0035}, [NCT03229876](ncbi-geo:NCT03229876){#intref0040}). CAR T cell responses against solid malignancies sometimes suffer from poor durability and persistence. However, this may be related to genome editing methods that rely on viral vectors for the random integration of transgenes, which can result in oncogenic transformation, unstable expression levels, and silencing ([@bib113]; [@bib184]). Recent advances in targeted genome editing into endogenous genomic loci offer the potential to alleviate some of these shortcomings. For example, it was demonstrated that targeted genomic integration of CAR genes into the endogenous TCR alpha chain constant region (TRAC) locus resulted in more uniform expression and increased potency of CAR T cells, when compared with random integration by retrovirus ([@bib51]). Furthermore, various CAR constructs were tested in respect to their influence on T cell phenotypes, including differentiation potential, exhaustion, activation, and memory. Disrupting the endogenous TCR through CRISPR-mediated knockout was reported to impair long-term persistence *in vivo* compared with CAR T cells with endogenous TCR, despite the advantage of avoiding potential alloreactivity of engineered T cells toward the host ([@bib176]). It is yet unclear if targeting CARs to TCR loci suffers from similar limitations. It is conceivable, however, that the lack of TCR expression itself results in this reduced long-term persistence. Lentiviral knock-in of engineered TCRs with CRISPR-mediated knockout of endogenous TCRα and β genes and the PDCD1 gene has recently been reported in a first-in-human phase I clinical trial, with results suggesting safety and durability of treatment ([@bib174]).

Adeno-associated viruses (AAVs) are exceptional at transducing hematopoietic cells and are able to deliver large quantities of DNA, thus providing a source for HDR templates for CRISPR-mediated transgene integration. In a recent study, a full TCRα and β variable domain was integrated into the TRAC locus using nucleofected PCR-amplified double-stranded DNA (dsDNA) and Cas9-ribonucleoprotein ([@bib146]) as well as parallel knockout of endogenous TCRα and β genes to avoid mispairing ([@bib155]). In addition to targeted integration, there are a number of clinical trials investigating concurrent knockout of immunomodulatory genes, such as PDCD1 ([NCT03399448](ncbi-geo:NCT03399448){#intref0045}, [NCR03545815](ncbi-geo:NCR03545815){#intref0050}). In order to achieve efficient on-target integration as well as multiplexed knockout of such genes, novel CRISPR systems have been used. In a single step, anti-CD22/19 CAR T cells with PDCD1 knockout were generated using the CRISPR-Cas12a system, all encoded by a singular knock-in knock-out (KIKO) vector, containing the crRNAs as well as the DNA template. Double knock-in of anti-CD19 and anti-CD22 CARs into primary human T cells was also achieved at high rates of up to ∼75%, whereas Cas9 edits were unable to achieve the same result (up to ∼5%) ([@bib37]). Double knock-in of large DNA constructs as well as multiplexed knockout of specific genes may be beneficial for treating complex cancers (e.g., in solid tumors with inhibitory tumor microenvironments). An alternative to gene ablation by concomitant knockout is reported in another study by Roth and colleagues, in which a pool of gene constructs that potentially enhance engineered T cell function is transfected alongside a TCR of defined specificity ([@bib145]). Aforementioned advances in nonviral DNA delivery enable the integration of large DNA fragments and thus, multiple genes. Here, the authors delivered a barcoded 36-member therapeutic knock-in library into the TRAC locus. T cell behavior in terms of proliferation and other functional parameters were assessed including experiments in which enriched T cells were extracted in a solid human tumor xenograft mouse model.

### CRISPR-Mediated B Cell Engineering {#sec1.5.2}

Engineering B cells to express precisely defined monoclonal antibodies against pathogens and disease would represent a powerful way to provide synthetic immunity. In contrast to T cell genome editing, B cell genome editing has only very recently started to emerge as a possible immunotherapy strategy. This is largely because most cellular therapy efforts have been focused on cancer indications, where T cells play a dominant role for therapeutic intervention. In addition, genomic modification of B cells has been much more difficult to achieve.

One of the first reports of editing primary human B cells attempted to knock-in targeted nucleotides with co-delivery of single-stranded DNA (ssDNA) oligonucleotides and electroporation of Cas9 RNP types ([@bib200]). Despite achieving efficiencies of 10% or more HDR, integration was limited to a few base-pairs. The authors also reported that insertions or deletions occurred much more frequently than what has been observed in other cells, pointing toward differences in the behavior of the DNA repair machinery in B cells compared with T cells. Generating larger knock-in seemingly required other tools and vectors. Extending the *ex vivo* culture as well as using AAV6 to deliver an HDR template, site-specific integration rates of up to 25% ([@bib90]) and 40% ([@bib88]) were achieved in primary human B cells. Johnson and colleagues also found that Cas9 mRNA delivery instead of RNPs may be detrimental to activation and growth regulation, possibly due to cytosolic RNA sensors ([@bib90]). With this groundwork completed, many research groups attempted to achieve the same goal in both murine and human B cells: introducing a transgene coding for a BCR variable region of defined specificity into the endogenous VH locus. In contrast to T cell therapies that were tested in immunodeficient mice, B cell therapies require a functioning immune system to assess homing to secondary lymphoid organs and additional stimulation to mature, differentiate, undergo somatic hypermutation, and class-switch recombination. The first study on integrating predefined BCRs into polyclonal murine B cells using Cas9 RNP and long ssDNA into the endogenous locus relied on targeting the intron downstream of the recombined VDJ~H~ to be able to use it partially as a 5′ homology arm, thus resulting in integration of bNAbs against HIV ([@bib76]). Concomitant CRISPR-mediated knock-out of endogenous murine Cκ prevented mispairing of the introduced antibody. Despite exciting and promising data, the study did not conclusively show immunization-dependent recruitment of engineered B cells, as well as antigen-dependent clonal expansion, the primary benchmark for creating an adoptive immunization. Further studies confirmed the inability of stimulated engineered cells to form a functional B cell memory response, despite the presence of memory phenotype markers, which is likely an artifact from *ex vivo* culture. A study in primary human B cells equally attempted to integrate HIV bnAbs into the endogenous locus, using a different strategy ([@bib189]). Here, the authors deleted approximately 1 megabase from the V gene locus while introducing an HDR template with homology arms 5′ and 3′ of the deletion in order to be able to target a polyclonal mixture of B cells. Although integration was achieved, editing efficiencies for this strategy remained extremely low at less than 0.1%. Although not directly integrating antibodies, another study attempted to engineer murine B cells to express chimeric BCRs to sense antigen and in response secrete a protein of interest ([@bib131]). Similar to other studies, it was found that HDR editing rates using the conventional B cell *ex vivo* culture protocol and dsDNA transfection was very low at less than 1%. By optimizing murine B cell culture and transfection, Moffett and colleagues achieved higher editing rates of ∼4% using dsDNA and ∼16% with AAV6, as well as co-expression of separate antibodies from both antibody loci, representing an important milestone in B cell editing ([@bib120]). Engineered B cells were transferred to immunocompromised RAG1^−/−^ mice, and although they persisted *in vivo* for an extended period and formed protective serum titers, the engineered cells did not actively respond to infection in a memory or plasma-cell-like manner. This is probably due to the B cell phenotype derived from *ex vivo* culture as well as the lack of T cell help in RAG^−/-^ mice. In a recent study, Nahmad and colleagues achieved high HDR rates using AAV-DJ/8 to deliver the HDR templates and engineered HIV-specific CD45.1 B cells, which were then transferred to immunocompetent CD45.2 mice ([@bib122]). These engineered B cells were traced in regard to persistence, indicating successful clonal expansion in response to antigen. A synonymously re-coded anti-HIV bnAb containing AID-hotspots was introduced to assess somatic hypermutation. Although some mutations may be attributed to AAV preparation and B cell engineering, patterns in enrichment of mutations that follow transfer and immunization were observed, implying an *in vivo* selection. Shortly after, another similar study used LPS to expand primary murine B cells, reproducing the results observed by Nahmad and colleagues, i.e., demonstrating expansion of engineered memory B cells and long-lived plasma cells, as well as somatic hypermutation ([@bib87]). This exciting progress is paving the way for B cell genome editing as a feasible translational strategy for synthetic immunity.

Conclusion {#sec2}
==========

Manipulation of the immune system in order to protect from infectious diseases has been performed for several centuries, with one of the first historical examples being the smallpox vaccine invented by Edward Jenner in 1796, which is considered the official founding of the field of immunology. Since then, the means used to manipulate immunity have changed profoundly catalyzed by a greater understanding of the molecular and cellular intricacies that govern immune function. As extensively reviewed here, the field of immunology is increasingly relying on novel methods in immune repertoire sequencing, immunoinformatics, and immunogenomic engineering, the result of which is the emergence of the transformative new field of systems and synthetic immunology, which offers the possibility to answer long-standing fundamental questions and to reprogram and engineer immunity.

Methods {#sec4}
=======

All methods can be found in the accompanying Transparent Methods supplemental file.

Figures 1--4 were created with [BioRender.com](http://BioRender.com){#interref0020}.
